Clinical Trial Update: ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating ARX-788 in HER2-positive metastatic breast cancer patients who previously received trastuzumab deruxtecan (T-DXd) is not yet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• ARX-788

Snippet

Sponsor: Fudan University | Conditions: Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING